Decoy Therapeutics
DCOY
23 hedge funds and large institutions have $22.8M invested in Decoy Therapeutics in 2021 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, reducing their positions, and 2 closing their positions.
500% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 2
489% more capital invested
Capital invested by funds: $3.88M → $22.8M (+$19M)
64% more funds holding
Funds holding: 14 → 23 (+9)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$3.15M |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
+$3.1M |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$2.46M |
| 4 |
SCM
Sio Capital Management
New York
|
+$2.35M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
-$93K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$30K |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
-$10K |
| 4 |
SIAG
Signet Investment Advisory Group
Providence,
Rhode Island
|
-$9K |
| 5 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
-$8K |
DCOY Hedge Fund Activity: Q1 2021 in Review
23 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q1 2021, worth a combined $22.8M — up 489% from $3.88M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new DCOY positions and 2 closed out — a net gain of 10 holders — while 7 added to existing stakes and 0 trimmed.
The largest buyer was Silverarc Capital Management, opening a new position worth an estimated $3.15M. The largest seller was Squarepoint, exiting entirely with an estimated $93K sold.
- 23 institutional investors held Decoy Therapeutics (DCOY) as of Q1 2021, up from 14 in Q4 2020.
- Funds reported $22.8M of Decoy Therapeutics stock for Q1 2021, up 489% quarter-over-quarter.
- 12 funds opened new Decoy Therapeutics positions in Q1 2021 and 2 closed out, a net change of +10 holders.
- The largest Decoy Therapeutics buyer in Q1 2021 was Silverarc Capital Management, an estimated $3.15M added.
- The largest Decoy Therapeutics seller in Q1 2021 was Squarepoint, an estimated $93K sold.
Based on aggregated 13F filings for Q1 2021.